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In a cystic ﬁbrosis mouse model, intestinal dysbiosis and
inﬂammation repress signaling through the bile acid–
activated nuclear receptor farnesoid X receptor. This
repression impairs feedback regulation of hepatic bile acid
synthesis and limits the capacity for homeostatic liver
regeneration.
BACKGROUND & AIMS: The bile acid (BA)-activated farnesoid
X receptor (FXR) controls hepatic BA synthesis and cell pro-
liferation via the intestinal hormone ﬁbroblast growth factor
19. Because cystic ﬁbrosis (CF) is associated with intestinal
dysbiosis, anomalous BA handling, and biliary cirrhosis, we
investigated FXR signaling in CF.
METHODS: Intestinal and hepatic expression of FXR target
genes and inﬂammation markers was assessed in Cftr null mice
and controls. Localization of the apical sodium-dependent BA
transporter was assessed, and BAs in gastrointestinal tissues
were analyzed. The CF microbiota was characterized and FXR
signaling was investigated in intestinal tissue and organoids.
RESULTS: Ileal murine ﬁbroblast growth factor 19 ortholog
(Fgf15) expression was strongly reduced in CF mice,FLA 5.6.0 DTD  JCMGH514 proof  20compared with controls. Luminal BA levels and localization
of apical sodium-dependent BA transporter was not affected,
and BAs induced Fgf15 up to normal levels in CF ileum,
ex vivo, and CF organoids. CF mice showed a dysbiosis that
was associated with a marked up-regulation of genes
involved in host–microbe interactions, including those
involved in mucin glycosylation, antimicrobial defense, and
Toll-like receptor signaling. Antibiotic treatment reversed the
up-regulation of inﬂammatory markers and restored intesti-
nal FXR signaling in CF mice. Conversely, FXR-dependent
gene induction in ileal tissue and organoids was repressed
by bacterial lipopolysaccharide and proinﬂammatory cyto-
kines, respectively. Loss of intestinal FXR activity was asso-
ciated with a markedly blunted hepatic trophic response to
oral BA supplementation, and with impaired repression of
Cyp7a1, the gene encoding the rate-limiting enzyme in BA
synthesis.
CONCLUSIONS: In CF mice, the gut microbiota represses in-
testinal FXR activity, and, consequently, FXR-dependent hepatic
cell proliferation and feedback control of BA synthesis. (Cell Mol
Gastroenterol Hepatol 2019;-:-–-; https://doi.org/10.1016/
j.jcmgh.2019.08.006)
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the proximal small intestine, BAs aid the absorption of di-
etary lipids, after which they are reabsorbed, mainly
through active uptake in the distal ileum via the apical
sodium-dependent BA transporter (ASBT; encoded by
SLC10A2).1 Although very little of the load entering the in-
testine escapes re-uptake, small amounts of BA pass through
the colon and are excreted in the feces. Fecal loss is
compensated for by de novo synthesis, which is regulated
through a ﬁnely tuned homeostatic control mechanism, to
maintain a near-constant body BA pool. One of the key el-
ements of this control mechanism is the activation of the
farnesoid X receptor (FXR) in ileal epithelial cells by
reclaimed BAs.2,3 Intestinal FXR activation induces the
expression of an array of genes involved in BA transport and
metabolism. Most importantly, BA reabsorption triggers the
production and release of ﬁbroblast growth factor (FGF)19.
This hormone, through activation of its hepatic receptor,
represses expression of CYP7A1, the gene encoding the
cholesterol 7a-hydroxylase that catalyzes the rate-limiting
step in cholic acid (CA) synthesis.4 The importance of this
feedback loop is underlined by the observation that in
FGF15 (the murine FGF19 ortholog)-deﬁcient mice, hepatic
BA synthesis and intestinal delivery are stimulated to a level
that exceeds the capacity for reabsorption, resulting in
enhanced fecal excretion.5 In addition, FGF15/19 has tro-
phic effects in the liver, which are crucial for liver regen-
eration after injury.6,7 Through its effects on hepatic BA
synthesis, FGF15/19 signaling may prevent cholestasis-
induced liver damage.8,9
Cystic ﬁbrosis (CF), an autosomal-recessive disease
caused by mutations in the CF transmembrane conductance
regulator (CFTR) gene, is characterized by focal biliary
cirrhosis, which in a subgroup of patients (approximately
30%) progresses to a clinically signiﬁcant, advanced stage of
CF-related liver disease (CFLD).10 Principally, this cholangi-
opathy is thought to be caused by obstruction of the intra-
hepatic bile ducts by mucoid secretions and accumulation of
hydrophobic BAs, but other factors, such as exposure to gut-
derived endotoxins, also may contribute.10–12 Bile of CF pa-
tients shows a relative increase in CA levels and a decrease in
the levels of secondary BAs, which is indicative of enhanced
de novo synthesis.13 This also is implied by the observation
that the body BA pool size of CF patients is normal to large,
despite the fact that, inmany CF patients, fecal BA excretion is
abnormally high, whereas plasma FGF19 levels are low.13,14
Fecal BA wasting, high biliary CA levels, and a mild chol-
angiopathy also have been observed in most CF mouse
models.15–17 These observations suggest that, perhaps
because of interrupted enterohepatic cycling of BAs, the FXR/
FGF19 signaling pathway is suppressed in CF. Indeed,
strongly reduced ilealAsbt and Fgf15 expression, indicative of
reduced BA uptake and FXR activation, was reported for 1 CF
mouse model.18 In this instance, low FXR/FGF15 signaling
was attributed to defective gallbladder emptying, which
severely limited intestinal delivery of BAs. Furthermore,
more circumstantial evidence for attenuated FXR/FGF15FLA 5.6.0 DTD  JCMGH514 proof  20signaling in CF was provided by one of our previous studies,
in which it was shown that dietary CA supplementation,
which is known to induce hepatocyte proliferation through
an FXR-/FGF15-dependent pathway, triggers a markedly
blunted response in CF mice.6,7,19 Assuming that the virtual
absence of this response in our CF mice is indeed linked to
low intestinal FGF15 production, our data imply that
enhanced intestinal delivery of BAs (as per diet) does not
correct FXR/FGF15 signaling. This led us to speculate that,
apart from defective gallbladder emptying, other factors may
contribute to impaired FXR/FGF15 signaling.
In recent years it has become apparent that the gut
microbiota, through modulation of intestinal FXR signaling,
is a key regulator of BA metabolism. In mice, intraluminal
microbial BA conversion appears to be a key determinant of
BA uptake and FXR activity because both eradication of the
microﬂora and colonization of the gut by probiotics were
shown to repress Fgf15 induction markedly.20–22 Further-
more, it was shown that bacterial endotoxins eliciting an
acute-phase response, repress hepatic FXR signaling, and
that FGF15 production is reduced in inﬂamed intestinal
tissue.23–26 Because murine CF models show distinct
quantitative and qualitative changes in the gut microbiota
(dysbiosis) and inﬂammation of the gut wall, it is conceiv-
able that BA biotransformation and/or exposure to endo-
toxins leads to a loss of FXR-dependent feedback control of
hepatic BA synthesis.27–29
Presently, we have investigated the role of the gut
microbiota in intestinal FXR signaling in CF mice. We show
that intestinal FXR signaling is attenuated markedly in CF
mice, despite normal luminal BA levels, and that repression
of FXR signaling persists upon supraphysiological BA
dosage, but that constraining bacterial colonization by
antibiotic treatment reduces the expression of inﬂammation
markers and normalizes Fgf15 expression and BA synthesis.Results
Intestinal FXR Signaling Is Impaired in CF Mice
The expression of FXR targets Fgf15 and Shp (Nr0b2)
was markedly lower in the ileum of CF mice compared with
littermate controls, whereas expression of Fxr (Nr1h4) itself
was similar between genotypes (Figure 1A). Congruent with
low intestinal FGF15 production, hepatic expression of
Cyp7a1 was enhanced in CF mice, whereas the expression of
the FGF15 receptor, Fgfr4, in the intestine and in the liver,
was not affected.November 2019  3:03 pm  ce DVC
Figure 1. FXR activity, ASBT localization, and taurocholic acid (TC)-dependent gene induction in the CF ileum.
(A) Expression of genes involved in bile acid signaling in the ileum (Fgf15, Shp, Fxr, Asbt, Fgfr4) and liver (shaded bars; Cyp7a1,
Fgfr4) of CF mice (Cftr-/-) and controls (Cftr N/N). Data represent expression in a CF animal relative to an age-/sex-matched
littermate control (means ± SE). The number of couples analyzed is indicated within/above each bar. a, P ¼ .005; b, P ¼ 0.001;
c, P ¼ .005; ns, P > .05 (paired ratio t test). (B) Immunohistochemical detection of ASBT in ileum of CF mice (Cftr-/-) and
controls (Cftr N/N). ASBT was localized at the apical aspect of epithelial cells of the villi, but was absent from crypts. (C) ASBT
was detected by Western analysis in brush-border membranes prepared from CF (-/-) and control (N/N) ileum. Both the
monomeric (46 kilodaltons) and dimeric form were detected. Numerals to the left of the blot refer to the molecular mass
(kilodaltons) of protein standards. ASBT abundance was quantiﬁed on the basis of the immune-reactive signal of both the
monomer and dimer (bar diagram). Data shown are means ± SE of 5 mice per genotype. d, P ¼ .03 (paired t test, 2-tailed).
(D) Induction of gene expression by TC in ileal tissue sections of CF mice (Cftr-/-) and controls (Cftr N/N). Data shown are
means ± SE. The number of biological replicates is indicated within/above each bar. e, Two-way analysis of variance indicated










2019 Impaired FXR Signaling in CF 3We hypothesized that a shortage of activating ligands may
have attenuated FXR signaling, possibly as a result of reduced
ASBT-mediated BA uptake. Therefore, we assessed the
expression and localization of ASBT. In the distal ileum, the
messenger RNA level of Asbt (Slc10a2) was similar in CF mice
and controls (Figure 1A). By immunohistochemistry, ASBTwas
localized at the apical plasma membrane of enterocytes in the
villi, but absent from cells in the crypts of Lieberkuhn, and this
pattern was unaffected by CFTR deﬁciency (Figure 1B).
Consistent with this localization pattern, ASBT was detected in
ileal brush-border membrane preparations, and appeared
more abundant in preparations from CF mice than in controls
(Figure 1C). When ileal tissue sheets of CF mice and controls
were exposed to taurocholic acid, Fgf15 was induced to a
similar extent in both groups (Figure 1D). These ﬁndings argue
against a primary defect in cellular BA uptake.CFTR Deﬁciency Affects the Composition, but
Not the Size, of the Luminal BA Pool
Because, ex vivo, FXR could be fully activated by exog-
enous BAs, we hypothesized that, in vivo, FXR activationFLA 5.6.0 DTD  JCMGH514 proof  20may be curtailed by a low luminal BA level, as was sug-
gested previously.18 Therefore, we assessed the levels of the
major BAs in the small intestinal lumen and in gastroin-
testinal tissues. This analysis showed that the BA content of
the small intestinal lumen was similar in CF mice and con-
trols (Figure 2A). The total amount of BA contained in the 4
compartments analyzed (representing most of the total
pool) also was similar between genotypes. However, the
composition of the luminal BA pool was changed by CFTR
deﬁciency: b-muricholic acid (b-MCA) levels were markedly
lower, whereas CA levels were higher than in control mice
(Figure 2B). We previously observed that hepatic CA syn-
thesis was enhanced in CF mice, leading to a similar shift in
the biliary b-MCA/CA ratio.17 Low ileal Fgf15 expression,
enhanced hepatic BA synthesis, and low biliary b-MCA/CA
ratios have been linked to enhanced intraluminal conver-
sion (deconjugation, dehydroxylation) of BAs upon gut
microbiota modulation by probiotic bacterial strains.22
However, arguing against enhanced intraluminal biotrans-
formation, the level of the secondary BA deoxycholic acid in
the small intestinal lumen was similar in CF mice and con-
trols (Figure 2B). Therefore, although the luminal BANovember 2019  3:03 pm  ce DVC
Figure 2. Partitioning of BAs in gastrointestinal tissues and composition of the luminal BA pool. (A) BA content,
normalized to body mass, of the small intestinal lumen and gastrointestinal tissues in CF mice and controls. The total levels
shown are a summation of the 4 separate compartments analyzed. (B) The relative contribution of the major BAs to the luminal
pool. Data shown are means ± SE of 5 Cftr N/N and 4 Cftr-/- mice. a, P ¼ .02; b, P ¼ .008 (t test, 2-tailed). DCA, deoxycholic
acid; Dist, distal; Prox, proximal.
4 Ikpa et al Cellular and Molecular Gastroenterology and Hepatology Vol. -, No. -composition in CF mice is indicative of enhanced hepatic BA
synthesis, in line with attenuated FXR/FGF15 signaling, it
does not provide evidence for reduced intestinal BA delivery
or enhanced BA biotransformation.CFTR Deﬁciency Affects the Host–Microbe
Interaction
Phylum-speciﬁc primer sequences within the bacterial
16S ribosomal RNA gene were used to assess the microbial
composition of the distal small intestine of CF and wild-type
mice. This showed that the bacterial community in the distal
small intestine consisted predominantly of Bacteroidetes
(58%) and Firmicutes (28%) (Figure 3A). The relative
abundance of other phyla was comparatively low. In CF
mice, the relative abundance of Bacteroidetes (22%) was
lower whereas that of Firmicutes (55%) was higher than in
controls (Figure 3A). It has been shown that dysbiosis im-
pacts intestinal architecture, leading to a lengthening of the
gut.30 Presently, we found that even though CF mice have a
signiﬁcantly lower body mass than wild types (Figure 3B),
their small intestine was 6% (normalized to body mass:
28%) longer than that of controls (Figure 3C).
The ileal expression of b-1,4-galactosyltransferase I
(B4galt1) and fuc a1-2 fucosyltransferase (Fut2), enzymes
that catalyze glycosylation of secreted mucin proteins, was
up-regulated in CF mice (Figure 3D). Fut2 is known to be
induced by bacterial colonization of the gut and was shown
to enhance fucosylation of mucins in CF mice, whereas,
interestingly, overexpression of B4galt1 was shown to in-
crease the Firmicutes to Bacteroidetes ratio in the mouse
gut.31–34 The expression of several inﬂammation markers,
including acute-phase proteins (Saa1, Saa3), chemokines/
cytokines (Ccl8, Cxcl9, the alarmin Il33), and antimicrobial
peptides (Ltf), also was higher in CF mice than in controls
(Figure 3D). Analysis of the ileal transcriptome indicated an
up-regulation of genes involved in Toll-like receptor (TLR)
signaling in CF mice, consistent with an altered
host–microbe interaction (Figure 3E).FLA 5.6.0 DTD  JCMGH514 proof  20Antibiotic Treatment Corrects FXR Signaling in
CF Mice
In view of the tentative role of the gut microbiota in the
regulation of FXR activity, we assessed the effect of anti-
biotic treatment on FXR signaling. Previously, it was shown
that complete eradication of the microﬂora strongly reduced
Fgf15 expression because the gut microbiota appears to
control the level of the FXR antagonist tauro-b-MCA.20
Therefore, a relatively mild antibiotic regimen was
applied, which previously was shown not to eradicate the
microﬂora fully, but to reduce small intestinal bacterial
overgrowth in CF mice.28 As a testament to its effectiveness,
this treatment markedly reduced the expression of typical
inﬂammation markers in CF mice (Figure 4A). Importantly,
it also restored Fgf15 and Shp expression in CF mice up to
the level observed in control animals, in which antibiotic
treatment did not induce Fgf15 or Shp (Figure 4B). In fact,
antibiotic treatment appeared to moderately reduce the
expression of Fgf15 in controls, suggesting that even this
mild treatment leads to increased tauro-b-MCA levels and
repression of FXR activity. If present, this antagonistic action
of tauro-b-MCA is apparently offset by a dominant FXR
stimulatory effect in CF mice. Concomitant with induction of
Fgf15, hepatic expression of Cyp7a1 was reduced in CF mice
(Figure 4C). The hepatic expression of the FGF15 receptor,
Fgfr4, was reduced moderately by antibiotic treatment in
both genotypes (Figure 4C).Bacterial Lipopolysaccharide and
Proinﬂammatory Cytokines Abrogate FXR-
Dependent Fgf15 Induction
In ileal organoids grown under microbe-free conditions,
the synthetic FXR agonist GW4064 strongly induced Fgf15,
and the level of expression attained was similar in CF and
control organoids (Figure 5A). Lipopolysaccharide (LPS) did
not notably affect GW4064-dependent expression of Fgf15
or Nr0b2 in organoids, but combined administration of










Figure 3. CFTR deﬁciency affects the host–microbe interaction. (A) The relative abundance of major bacterial phyla in the
distal small intestine of CF mice and controls. Box-and-whisker plot showing means, range, and 5th–95th percentile of 6
animals per genotype. a, P ¼ .048; b, P ¼ .047 (t test, 2-tailed). (B) Body mass of male and female CF mice (Cftr-/-) and
controls (Cftr N/N). Data shown are means ± SE. The number of animals per group is indicated within each bar. c, Two-way
analysis of variance indicated that CFTR loss had a statistically signiﬁcant (P < .0001) effect on body mass. (C) Length of the
small intestine (SI) in male and female CF mice (Cftr-/-) and controls (Cftr N/N). Data shown are means ± SE. The number of
animals per group is indicated within each bar. d, Two-way analysis of variance indicated that CFTR loss had a statistically
signiﬁcant (P ¼ .03) effect on intestinal length, independent of sex. (D) Transcript levels of genes involved in the host–microbe
interaction in ileum of CF mice, relative to sex-matched littermate controls. Data shown are means ± SE of 6 couples. *P < .05,
**P < .01, and ***P < .001 (paired ratio t test, 2-tailed). (E) Gene set enrichment analysis enrichment plot of the Kyoto
Encyclopedia of Genes and Genomes (KEGG) Toll-like receptor signaling gene set.
2019 Impaired FXR Signaling in CF 5lowered GW4064-dependent induction of Nr0b2, and also
tended to repress induction of Fgf15 (Figure 5B). In ileal
tissue explants, LPS abrogated GW4064-dependent Fgf15
expression, in line with previous data showing that proin-
ﬂammatory cytokines suppress intestinal FXR activity
(Figure 5C).35Impaired Intestinal FXR Signaling Reduces
BA-Dependent Hepatic Cell Proliferation
FGF15-dependent hepatic cell proliferation was shown
to promote liver regeneration after injury, and it wasFLA 5.6.0 DTD  JCMGH514 proof  20proposed that this intestine–liver signaling axis also drives
homeotrophic liver growth/repair.6,7,36 It was shown that,
through activation of this axis, dietary CA supplementation
increases liver mass.36
To investigate whether impaired FXR/retinoid X recep-
tor signaling in the CF intestine affects this intestine–liver
signaling axis, we assessed the effect of dietary CA sup-
plementation on liver mass, and intestinal and hepatic
expression of FXR target genes. We found that CA supple-
mentation strongly induced Fgf15 in both genotypes, but
that this effect was markedly more pronounced in control
than in CF mice (Figure 6A). FGF15 protein was detectableNovember 2019  3:03 pm  ce DVC
Figure 4. The effect of antibiotic
treatment on intestinal and hepatic
gene expression. (A) The effect of
antibiotic treatment on the expression
of typical inﬂammation markers in the
ileum of CF mice. Data shown are
means ± SE of 6 (Conventional) or 4
(Antibiotics) animals per group. **P <
.01 (Mann–WhitneyU test, 2-tailed). (B)
The effect of antibiotic treatment on
ileal Fgf15 and Shp expression in CF
mice (Cftr-/-) and littermate controls
(Cftr N/N). Data shown are means ±
SE. The number of animals per group
is indicated within/above each bar. a,
Two-way analysis of variance indi-
cated a statistically signiﬁcant inter-
action between antibiotic treatment
and Cftr genotype for Fgf15 expres-
sion (P ¼ .007), implying that loss of
CFTR affects the response to anti-
biotic treatment. (C) The effect of
antibiotic treatment on hepatic
Cyp7a1 and Fgfr4 expression (means
± SE). The number of animals per
group is indicated within/above each
bar. (b) Two-way ANOVA indicated
that antibiotic treatment reduced he-
patic Cyp7a1 (P ¼ .02) expression. (c)
Two-way ANOVA indicated that
antibiotic treatment reduced
hepatic Fgfr4 expression (P ¼ .02).
Gapdh, glyceraldehyde-3-phosphate
dehydrogenase.
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Figure 5. Proinﬂammatory signaling inhibits FXR-dependent gene expression in mouse ileum. (A) Induction of gene
expression in ileal organoids derived from CF mice (Cftr-/-) and controls (Cftr N/N). Data shown are means ± SE of 3 technical
replicates per group. a, Two-way analysis of variance indicated that treatment with the FXR agonist GW4064 signiﬁcantly
enhanced Fgf15 expression (P ¼ .0002), independent of genotype. (B) Induction of Fgf15 and Shp expression by GW4064 in
the presence or absence of LPS, or the cytokines (CKs) interferon g, interleukin 1b, and tumor necrosis factor a (CKs), in ileal
organoids. Data show the level of gene expression relative to the level of expression in the absence of GW4064. Data shown
are means ± SE of 4–6 technical replicates. b, One-way analysis of variance indicates that the combination of cytokines
signiﬁcantly reduced GW4064-dependent Shp expression (P ¼ .02, Tukey multiple comparisons test). (C) Induction of Fgf15
expression by GW4064 in the presence or absence of LPS in ileal tissue. Data show the level of gene expression relative to the
level of expression in the absence of GW4064. Data shown are means ± SE of 4 biological replicates. c, One-way analysis of
variance indicates that LPS signiﬁcantly reduced GW4064-dependent Fgf15 expression (P ¼ .007, Tukey multiple compari-
sons test).
2019 Impaired FXR Signaling in CF 7by Western analysis only in ileal tissue lysates of CF and
control mice fed CA, and levels were signiﬁcantly lower in
CF mice than in controls (Figure 6B). In mice fed a standard
diet we were unable to detect FGF15 protein in either ge-
notype, in line with the comparatively low transcript levels.
In control mice, the strong stimulation of FGF15 production
elicited by CA supplementation was associated with a
marked increase in liver mass (Figure 6C). In contrast, in CF
mice, this trophic response was lost completely. In accord
with the low FGF15 production observed in CF mice,
Cyp7a1 expression was repressed much less effectively in
CA-fed CF mice than in controls (Figure 6D). However, the
regulation of genes that are controlled (predominantly)
through hepatic FXR was not notably affected: CA supple-
mentation repressed Cyp8b1 expression and induced he-
patic Shp to a similar extent in CF mice and controls
(Figure 6D).2,5,37Discussion
This study shows that signaling through the BA-
activated nuclear receptor FXR is impaired markedly in
the distal small intestine of CF mice. Impaired intestinal
FXR signaling compromised BA-dependent regulation of
hepatic cell proliferation and BA synthesis. This defect was
associated with dysbiosis and an up-regulation of genes
involved in host–microbe interactions and innate immunity.
Antibiotic treatment reduced the expression of inﬂamma-
tion markers and restored FXR activity in the CF ileum.
FXR-dependent gene induction was not affected in CF
organoids (grown under sterile conditions), but treatment
with LPS or proinﬂammatory cytokines provoked a CF-like
repression of FXR signaling in non-CF ileal tissue and
organoids, respectively. These data suggest that aFLA 5.6.0 DTD  JCMGH514 proof  20CF-related inﬂammatory response represses signaling
through FXR.
We observed strong repression of Fgf15 and Nr0b2, 2 key
targets of the BA-activated nuclear receptor FXR, in ileum of
CF mice. Indeed, based on our transcriptome data, both of
these FXR targets rank among the most strongly down-
regulated genes in the CF intestine.38 In line with a role of
the gut microbiota in the down-regulation of FXR signaling,
we observed a dysbiosis in CF mice and found that contain-
ment of bacterial growth (by antibiotic treatment) enhanced
FXR signaling speciﬁcally in CFmice. Loss of CFTR-dependent
chloride and bicarbonate secretion in the gut leads to luminal
dehydration and acidiﬁcation, which, in turn, leads to aber-
rant mucus production.39 Mucus plugging, in conjunction
with maldigestion and malabsorption, and a protracted in-
testinal transit, is thought to promote microbial colonization
of the small intestine.40 In our CF mice, dysbiosis was chieﬂy
characterized by an increase in the Firmicutes to Bacter-
oidetes ratio, as has been observed similarly inmurinemodels
of colitis.41,42 It was associated with an up-regulation of
inﬂammation markers and gene set enrichment analysis
indicated TLR activation. The observed up-regulation of the
TLR-regulated Fut2, an enzyme that catalyzes fucosylation of
secreted mucin proteins, also points toward an altered
host–microbe interaction.31,34 Because the glycosyl moieties
of mucins are metabolized by bacteria, the activity of trans-
ferases such as Fut2 and B4galt1 may have a marked impact
on the gut microbiota. For instance, a modest overexpression
ofB4galt1, as observed similarly in our CFmice, was shown to
be sufﬁcient to signiﬁcantly increase the Firmicutes to Bac-
teroidetes ratio in the mouse gut, whereas deﬁciency of
another glycosyltransferase, C1galt1, was shown to shift this
ratio in the opposite direction.30,33 Furthermore, aberrant
mucin glycosylation and attendant changes in the gutNovember 2019  3:03 pm  ce DVC
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tion, suggesting that the intestinal lengthening observed in CF
mice may have similar causes.30,43
Both hepatic and intestinal FXR signaling were shown
previously to be strongly repressed by bacterial endotoxins
and proinﬂammatory cytokines.23–25,35 We found that LPS
abrogated FXR-dependent Fgf15 induction in non-CF ileum,
mimicking the strong repression of FXR activity observed
in vivo in the CF intestine. Conversely, FXR activity was
restored in CF tissue, ex vivo, and in CF organoids, indicating
that the repression is readily reversible. Proinﬂammatory
cytokines, but not LPS, repressed FXR-dependent gene in-
duction in organoids, suggesting that the action of LPS in
tissue depends on cytokine release from nonepithelial cell
types, and/or that expression of genes required for LPS
signaling, such as TLR4, is lost in epithelial cell cultures.
These data indicate that a bacterial endotoxin-induced in-
ﬂammatory response can impair FXR function in the gut,
and strongly suggest that local inﬂammation of the gut wall
represses FXR activity in the CF ileum. In this context, it is of
interest that CF mice, including the strain presented here,
also show impaired intestinal peroxisome proliferator-
activated receptor-g signaling because inactivation of
peroxisome proliferator-activated receptor-g was shown to
promote colonization of the gut by (LPS-producing) gram-
negative facultative anaerobes.38,44–46
It has been reported that intraluminal bacterial modiﬁ-
cation (deconjugation, dehydroxylation) of BAs may reduce
their uptake via ASBT and, consequently, lower FXR activ-
ity.22 However, the intraluminal levels of the secondary BA
deoxycholic acid were similar in CF mice and controls,
which argues against enhanced microbial metabolism of
BAs. Moreover, although we and others previously have
shown that fecal BA excretion is approximately 2-fold higher
in CF mice than in controls, this amounts to only a modest
reduction in the overall efﬁcacy of the absorptive process
because normally only 3%–5% of the dose entering the
intestine through biliary secretion is lost.15,16,47 It follows
that the efﬁcacy of the absorptive process is decreased from
95% in controls to approximately 90% in CF mice, and it is
difﬁcult to envisage how such a modest reduction in BA
absorption could lead to the strong repression of FXR target
genes observed. Similarly, the notion that intraluminal
bioconversion limits FXR activity is difﬁcult to reconcile
with the observation that dietary CA supplementation did
not fully restore FXR activity because the dose used in these
experiments results in luminal CA levels well in excess of
those occurring naturally and is predicted to saturate
carrier-mediated absorption.48 To exclude a defect in the
latter process, we ascertained that the apical localization of
this carrier, ASBT, was not affected. In fact, ASBT levels were
higher (approximately 1.4-fold) in brush-border membrane
preparations of CF mice than of controls. Conceivably, this
increase is linked to decreased Fgf15 expression because it
has been shown that FGF15/hepatic receptor of FGF15
(FGFR4) signaling reduces ASBT protein abundance in
mouse ileum.49 Collectively, these data suggest that intes-
tinal FXR activity is limited primarily by a defect located
downstream of cellular BA uptake.FLA 5.6.0 DTD  JCMGH514 proof  20In mice, complete FGF15 deﬁciency was shown to mark-
edly enhance hepatic Cyp7a1 expression and the fecal
excretion of BAs.5 Our current ﬁndings indicate that low
FGF15 production and impaired feedback regulation of BA
synthesis similarly may contribute to the fecal BA wasting
observed in CF mice.15,16 Congruent with this concept, we
have observed previously that the antibiotics used at present
reduce the fecal excretion of cholic acid in CF mice.50 This
model also may explain why some have observed that biliary
BA secretion is enhanced in CFmice.16 It also accounts for the
fact that the presentation of fecal BA wasting in patients is
quite variable because any factor that affects host–microbe
interactions and gut immunity may modulate BA handling.
The same probably holds true for CF mouse models, and this
may explain why effects on fecal excretion and biliary
secretion of BAs may be subtle and escape detection.17,18,51
One key confounding factor is the diet: CF mice almost
invariably are reared on liquid elemental formulations or oral
laxatives (to prevent intestinal obstruction), both of which
markedly affect the bacterial load in the gut.52,53 Indeed,
recently, we showed that application of an oral laxative with a
high polyethylene glycol/low electrolyte composition (ie,
different from the formulation used in our present study),
reduced fecal BA excretion in CF (Cftrtm1Unc) mice.54
We observed that the hepatic trophic response, induced
by BA-dependent induction of intestinal Fgf15, is strongly
suppressed in CF mice. Because this signaling axis was
proposed to play a role in the homeostatic control of liver
regeneration after injury, we surmise that an intestinal FXR
signaling defect also may be of consequence for the patho-
physiology of CFLD.6,7 Impaired intestinal FXR signaling also
may enhance exposure of the liver to endotoxins because it
was shown that FXR deﬁciency, in conjunction with dys-
biosis, compromises epithelial barrier function.55 Congruent
with this scenario, it was shown that a chemically induced
colitis exacerbates liver disease in CF mice, and a pathogenic
role of gut-derived bacterial products was indicated.12
Decreased intestinal FGF19 production and an attendant
increase in BA synthesis may contribute further to the
progression of the cholangiopathy.6,8,9 Indeed, although
focal biliary cirrhosis is thought to result primarily from the
loss of local CFTR activity, it also is apparent that some
gastrointestinal manifestations of CF that are likely to
impact the gut microbiota, such as pancreatic insufﬁciency
and a history of meconium ileus, seem to predispose to the
development of CFLD.11,56,57 Collectively, these data imply
that intestinal inﬂammation and FXR dysfunction may
contribute to the pathogenesis of biliary cirrhosis, suggest-
ing that therapeutic interventions aimed at restoring FXR
signaling may slow its progression.Methods
Animal Procedures and Tissue Collection
CF mice (Cftrtm1Cam; congenic FVB/n) and littermate
controls were maintained in individually ventilated cages in
an environmentally controlled facility at the Erasmus
Medical Center. Animals were reared on a low-ﬁber diet
(C1013; Altromin, Lage, Germany) and a polyethyleneNovember 2019  3:03 pm  ce DVC
Figure 6. The effect of dietary BA supplementation on FXR signaling. CF mice (Cftr-/-) and controls (Cftr N/N) were fed a
CA-enriched or a conventional diet. (A) Induction of intestinal Fgf15 by CA. Data shown are means ± SE. The number of
animals per group is indicated within/above each bar. Control data as shown in Figure 4B. a, Two-way analysis of variance
indicated a signiﬁcant interaction between CA intake and Cftr genotype for the effect on Fgf15 expression (P ¼ .0001), implying
that loss of CFTR affects the response to dietary CA supplementation. (B) FGF15 protein was below detection levels in jejunal
and ileal tissue of mice fed a control diet. CA feeding increased FGF15 levels in both CF mice and controls, but this effect was
more pronounced in controls. Numerals to the left of the blot refer to the molecular mass (kilodaltons) of protein standards. The
bar diagram shows the intensity of the ﬂuorescent signal of the FGF15 band relative to the b-actin signal of the same sample.
Data shown are means ± SE of 3 animals per genotype. b, P ¼ .02 (t test, 2-tailed) (C) Effect of CA supplementation on liver
mass. Data shown are means ± SE. The number of animals per group is indicated within/above each bar. c Two-way analysis
of variance indicated a statistically signiﬁcant interaction between CA feeding and Cftr genotype for the effect on liver mass
(P ¼ .004), implying that loss of CFTR affects the response to dietary CA supplementation. (D) Effect of dietary BA supple-
mentation on hepatic gene expression. Data shown are means ± SE. The number of animals per group is indicated within/
above each bar. d Two-way analysis of variance indicated that CA feeding suppressed hepatic Cyp7a1 (P ¼ .001) and Cyp8b1
(P ¼ .0001) expression, but enhanced expression of Shp (P ¼ .003). Gapdh, glyceraldehyde-3-phosphate dehydrogenase.
2019 Impaired FXR Signaling in CF 9glycol/electrolyte dinking solution to prevent intestinal
obstruction in early life (22.8 g/L polyethylene glycol 4000:
40 mmol/L Na2SO4, 75 mmol/L NaHCO3, 10 mmol/L NaCl,
and 10 mmol/L KCl).58 In some instances, before further
experimentation, animals were administered either a diet
supplemented with CA (0.5%), or drinking water supple-
mented with ciproﬂoxacin (0.3 g/L) and metronidazole (0.5
g/L) for 15 days.28 Intake of food and water was monitored
during this period and shown to be comparable between
genotypes (not shown).
Before tissue collection, animals (age, 13–22 wk) were
kept on normal drinking water (or, when applicable,
drinking water supplemented with antibiotics) for >4 days,
which is well tolerated by adult CF mice. Animals were
anesthetized (120 mg/kg ketamine, 20 mg/kg xylazine;
intraperitoneally), and the intestinal tract and liver were
collected, and ﬂushed or rinsed, respectively, with ice-cold
saline. Sampling from a CF animal and a sex-matched
littermate control was performed within a time window ofFLA 5.6.0 DTD  JCMGH514 proof  2020 minutes, and between 12:00 and 14:00 hours, to control
for diurnal variations in gene expression. Experiments were
approved by the Independent Committee on Ethical Use of
Experimental Animals (Rotterdam, The Netherlands), ac-
cording to national guidelines (120-0402/0501/0503/
0902; 141-1204/1208/1210).Intestinal and Hepatic Gene Expression
For gene expression studies, 2 ileal sections (length, 3–5
mm) were collected, at 0.5–1.5 and 5–6 cm proximal to the
ileocecal valve. Liver tissue was sampled from the right
lobe. Tissue homogenization, RNA extraction, and quanti-
tative reverse-transcriptase polymerase chain reaction
(primer sequences shown in Table 1) was performed as
described elsewhere.59 Median values of assays performed
in triplicate were used to determine gene expression levels,
relative to Gapdh. To correct for regional differences in gene
expression in the distal small intestine, mean values of theNovember 2019  3:03 pm  ce DVC
10 Ikpa et al Cellular and Molecular Gastroenterology and Hepatology Vol. -, No. -relative expression levels at the 2 sampling locations are
presented.
Gut Microbiota Analysis
The content of the distal small intestine (one third of its
total length) was collected by ﬂushing with 10 mL of ice-
cold phosphate-buffered saline, and samples were stored
at -20C until further analysis. After thawing, the intestinal
contents were collected by centrifugation (4000  g; 30
min), and microbial DNA was extracted using an RTP Bac-
teria DNA Mini Kit, according to the manufacturer’s in-
structions (Stratec Molecular, Berlin, Germany). Real-time
polymerase chain reaction was performed on the isolated
DNA using phylum-speciﬁc primer sequences within the 16S
ribosomal RNA gene to assess the composition of the ileal
microbiota, as described in detail elsewhere.60
Organoid Culture
Organoid cultures were initiated from isolated intestinal
crypts, harvested from the distal small intestine (up to 8-cm
proximal to the ileocecal valve), as described in detail
elsewhere.61 Brieﬂy, organoids were cultured, embedded in
Matrigel (Corning Life Sciences, Amsterdam, The
Netherlands), in medium containing epidermal growth fac-
tor, noggin, R-spondin 1, and WNT3a. Cell differentiation
was prompted by culturing in the absence of WNT3a, in
medium containing the WNT secretion inhibitor IWP-2 (10
mmol/L; Tocris, Abingdon, United Kingdom).Ex Vivo FXR-Dependent Induction of Intestinal
Gene Expression
For assessing BA-dependent induction of gene expres-




















FLA 5.6.0 DTD  JCMGH514 proof  20collected 3–5 cm proximal to the ileocecal valve. Mucosal
tissue sheets were mounted in Ussing chambers and bathed
in modiﬁed Meyler solution, gassed with 95% O2–5% CO2,
at 37C, as described previously.62 After a 40-minute
equilibration period, the solution bathing the luminal side
of 1 tissue sheet was supplemented with taurocholic acid
(0.25 mmol/L), while the other section served as vehicle
(water) control. After 1 hour, tissue was collected and
processed for RNA extraction (see Intestinal and Hepatic
Gene Expression). For assessing the effect of bacterial LPS
on FXR-dependent gene induction, ileal tissue sections were
incubated for 18 hours with the FXR agonist GW4064
(1 mmol/L; Selleck Chemicals, Munich, Germany), in the
presence or absence of LPS (Salmonella enterica; 10 mg/mL),
in Dulbecco’s modiﬁed Eagle medium, supplemented with
fetal calf serum (10%), penicillin (50 U/mL), and strepto-
mycin (0.005%), at 37C in 5% CO2.
Organoids, cultured for 5 days in differentiation medium
(see Organoid Culture), were cultured for 20 hours in the
presence or absence of LPS (10 mg/mL) or a combination of
cytokines (200 ng/mL murine interferon g, 50 ng/mL tu-
mor necrosis factor a, 10 ng/mL IL1b; Peprotech, Rocky
Hill, NJ). FXR-dependent gene induction was prompted by
the addition of GW4064 (1 mmol/L, 4 h). Organoids were
harvested in ice-cold phosphate-buffered saline, collected by
centrifugation (300 X g, 5 min), and processed for RNA
extraction.59 Gene expression was assessed as outlined
above for tissue, using Ywhaz expression as a reference.Detection of ASBT and FGF15 by Western Blot
Analysis
For ASBT detection, brush-border membrane fractions
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2019 Impaired FXR Signaling in CF 11described in detail elsewhere.63 For FGF15 detection, ileal
tissue was excised 2–5 cm proximal to the ileocecal valve,
and epithelial cells were gently scraped off the underlying
connective tissue layers, using a glass coverslip. Cells were
lysed by brief sonication (three 15-s bursts) in ice-cooled
NaCl (150 mmol/L), Tris/HCl pH 7.6 (25 mmol/L), Triton
(Sigma Aldrich, St. Louis, MO) X-100 (1%), sodium deoxy-
cholate (1%), sodium dodecyl sulfate (0.1%), NaF (5 mmol/
L), and Na3VO4 (3 mmol/L), supplemented with a protease
inhibitor cocktail. Brush-border and whole-cell preparations
were subjected to sodium dodecyl sulfate–polyacrylamide
gel electrophoresis, and proteins were transferred to a
nitrocellulose membrane. ASBT was detected using a poly-
clonal antibody directed against hamster ASBT.64 FGF15
was detected using a polyclonal antibody directed against
an epitope of mouse origin (SC27177; Santa Cruz, Dallas,
TX). A ﬂuorescent dye–labeled secondary antibody and the
Odyssey infrared imaging system (Application software 3;
Licor Biosciences, Bad-Homburg, Germany) were used for
quantiﬁcation. Detection of b-actin served as loading control
(SC47778; Santa Cruz).
Immunohistochemistry
Paraformaldehyde-ﬁxed, parafﬁn-embedded tissue sec-
tions (5 mm) of the distal small intestine (excised 2–4 cm
proximal to the ileocecal valve) were probed with a poly-
clonal antiserum directed against hamster ASBT (1:100;
see above), followed by an anti-rabbit IgG horseradish-
peroxidase–conjugated secondary antibody. Immune
complexes were visualized by incubation with 3,3-
diaminobenzidine tetrahydrochloride, in sections counter-
stained with hematoxylin (Zeiss [Oberkochen, Germany]
Axioskop 20 microscope and a Nikon [Amsterdam,
Netherlands] DS-U1 camera).
Analysis of BA in Luminal Eluates and
Gastrointestinal Tissues
Tissue was collected from anesthetized animals, as out-
lined above. To collect its contents, the intestinal lumen was
rinsed with 10 mL ice-cold phosphate-buffered saline. The
intestine subsequently was divided into a proximal section
(two thirds of the entire length) and a distal section. Tissue
samples and eluates were weighed and the former were
homogenized in ice-cold phosphate-buffered saline. After
samples were saponiﬁed in NaOH (1 mol/L, in methanol),
BAs were extracted on Sep-Pak C18 cartridges (Mallinck-
rodt Baker, Staines-Upon-Thames, United Kingdom). BAs
were analyzed as unconjugated methyl ester-trimethylsilyl
ether derivatives by capillary gas chromatography.65
Data Analysis
The statistical signiﬁcance of differences between mean
levels of gene expression, ASBT and FGF15 abundance, tis-
sue BA levels, and microbial composition in CF and controls
were analyzed by Student t test (2-sided). The effect of
GW4064, cytokines, and LPS on gene expression was
analyzed by 1-way analysis of variance. The effect of BA and
antibiotic treatment on gene expression in CF mice andFLA 5.6.0 DTD  JCMGH514 proof  20controls, and the effect of GW4064 on gene expression in CF
and control organoids, was analyzed by 2-way analysis of
variance. The Mann–Whitney U test was used to assess
differences between data sets that were not normally
distributed. Statistical analyses were performed using
GraphPad Prism 5 (GraphPad Software, San Diego, CA).
For gene set enrichment analysis (Broad Institute,
Cambridge, MA), transcriptome data from 3 sex-matched (2
females/1 male) littermate couples were used (NCBI-GEO
repository GSE92991).38 Gene set enrichment analysis was
used to compare the expression proﬁle observed in the data
set with a priori–deﬁned gene sets that represent well-
deﬁned biological processes (Kyoto Encyclopedia of Genes
and Genomes curated gene sets; Molecular Signatures
database 6.1; Broad Institute).66 The degree to which genes
in the predeﬁned set are over-represented at the extremes
of the ranked list of transcripts in the sample is reﬂected by
the enrichment score.67 To adjust for differences in gene set
size, enrichment scores were normalized and statistically
assessed using a correction for multiple hypotheses testing.
The reported false-discovery rate is the estimated proba-
bility that the observed normalized enrichment score con-
stitutes a false-positive result.References
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